CG Oncology (CGON) Share-based Compensation (2023 - 2026)
CG Oncology's (CGON) quarterly Share-based Compensation came in at $1.3 million in Q1 2026, down 74.76% YoY from $5.2 million in Q1 2025, and down 81.91% on a QoQ basis from $7.2 million in Q4 2025.
CG Oncology (CGON) Share-based Compensation (2023 - 2026) Analysis & Trends
CG Oncology (CGON) has 4 years of Share-based Compensation data on file, last reported at $1.3 million in Q1 2026.
- Quarterly Share-based Compensation fell 74.76% year-over-year to $1.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.3 million (down 91.35% YoY) and the FY2025 annual result came in at $26.7 million, up 133.96% from the prior year.
- Share-based Compensation fell to $1.3 million in Q1 2026, from $7.2 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $7.3 million in Q3 2025 to a low of $177000.0 in Q2 2023.
- A 4-year average of $3.1 million and a median of $2.2 million in 2024 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 1168.93% — and 2026, when it tumbled 74.76%.
- Tracing CGON's Share-based Compensation over 4 years: stood at $778000.0 in 2023, then surged by 541.39% to $5.0 million in 2024, then soared by 44.03% to $7.2 million in 2025, then tumbled by 81.91% to $1.3 million in 2026.
- The last three Share-based Compensation figures came in at $1.3 million (Q1 2026), $7.2 million (Q4 2025), and $7.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | CG Oncology | 6.63 Bn | 6.63 Bn | -2.77 Mn | 14.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 14.33 Mn |
| Jun 30, 2026 | 14.33 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Mar 31, 2026 | 1.30 Mn |
| Dec 31, 2025 | 7.19 Mn |
| Dec 31, 2025 | 7.19 Mn |
| Sep 30, 2025 | 7.33 Mn |
| Sep 30, 2025 | 7.33 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Jun 30, 2025 | 7.01 Mn |
| Mar 31, 2025 | 5.15 Mn |
| Mar 31, 2025 | 5.15 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Dec 31, 2024 | 4.99 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Sep 30, 2024 | 2.65 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Jun 30, 2024 | 2.25 Mn |
| Mar 31, 2024 | 1.52 Mn |
| Mar 31, 2024 | 1.52 Mn |